Pitcairn’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-10,192
| Closed | -$1.43M | – | 67 |
|
|
2025
Q3 | $1.43M | Buy |
10,192
+2,738
| +37% | +$370K | 0.11% | 162 |
|
|
2025
Q2 | $936K | Buy |
+7,454
| New | +$929K | 0.06% | 267 |
|
|
2024
Q4 | – | Sell |
-1,099
| Closed | -$213K | – | 711 |
|
|
2024
Q3 | $213K | Sell |
1,099
-317
| -22% | -$66.3K | 0.01% | 675 |
|
|
2024
Q2 | $328K | Sell |
1,416
-175
| -11% | -$38K | 0.02% | 560 |
|
|
2024
Q1 | $343K | Sell |
1,591
-61
| -4% | -$14.3K | 0.02% | 541 |
|
|
2023
Q4 | $427K | Sell |
1,652
-55
| -3% | -$13.5K | 0.03% | 446 |
|
|
2023
Q3 | $439K | Buy |
1,707
+53
| +3% | +$14.2K | 0.04% | 405 |
|
|
2023
Q2 | $471K | Sell |
1,654
-14
| -0.8% | -$4.17K | 0.04% | 372 |
|
|
2023
Q1 | $464K | Sell |
1,668
-30
| -2% | -$8.3K | 0.04% | 358 |
|
|
2022
Q4 | $470K | Buy |
1,698
+1
| +0.1% | +$282 | 0.05% | 331 |
|
|
2022
Q3 | $453K | Sell |
1,697
-1,351
| -44% | -$287K | 0.05% | 309 |
|
|
2022
Q2 | $622K | Sell |
3,048
-176
| -5% | -$36K | 0.07% | 246 |
|
|
2022
Q1 | $679K | Sell |
3,224
-618
| -16% | -$134K | 0.06% | 275 |
|
|
2021
Q4 | $922K | Sell |
3,842
-4,077
| -51% | -$1.05M | 0.06% | 226 |
|
|
2021
Q3 | $2.24M | Buy |
7,919
+663
| +9% | +$217K | 0.15% | 90 |
|
|
2021
Q2 | $2.51M | Sell |
7,256
-1,107
| -13% | -$335K | 0.17% | 84 |
|
|
2021
Q1 | $2.34M | Sell |
8,363
-480
| -5% | -$129K | 0.17% | 94 |
|
|
2020
Q4 | $2.17M | Buy |
8,843
+2,110
| +31% | +$544K | 0.17% | 88 |
|
|
2020
Q3 | $1.91M | Buy |
6,733
+1,794
| +36% | +$500K | 0.16% | 89 |
|
|
2020
Q2 | $1.32M | Buy |
4,939
+2,680
| +119% | +$806K | 0.13% | 109 |
|
|
2020
Q1 | $715K | Buy |
2,259
+311
| +16% | +$94.4K | 0.08% | 140 |
|
|
2019
Q4 | $578K | Sell |
1,948
-1,670
| -46% | -$463K | 0.05% | 233 |
|
|
2019
Q3 | $842K | Buy |
3,618
+227
| +7% | +$52.9K | 0.08% | 156 |
|
|
2019
Q2 | $793K | Sell |
3,391
-56
| -2% | -$12.9K | 0.08% | 158 |
|
|
2019
Q1 | $815K | Sell |
3,447
-186
| -5% | -$58.6K | 0.09% | 137 |
|
|
2018
Q4 | $1.09M | Sell |
3,633
-223
| -6% | -$71.2K | 0.12% | 107 |
|
|
2018
Q3 | $1.36M | Sell |
3,856
-157
| -4% | -$54.1K | 0.14% | 97 |
|
|
2018
Q2 | $1.17M | Sell |
4,013
-236
| -6% | -$66.3K | 0.12% | 102 |
|
|
2018
Q1 | $1.16M | Sell |
4,249
-264
| -6% | -$81.9K | 0.12% | 102 |
|
|
2017
Q4 | $1.44M | Sell |
4,513
-70
| -2% | -$22.5K | 0.14% | 91 |
|
|
2017
Q3 | $1.44M | Sell |
4,583
-240
| -5% | -$71.1K | 0.16% | 87 |
|
|
2017
Q2 | $1.31M | Sell |
4,823
-353
| -7% | -$93.3K | 0.16% | 89 |
|
|
2017
Q1 | $1.42M | Sell |
5,176
-424
| -8% | -$120K | 0.17% | 85 |
|
|
2016
Q4 | $1.59M | Sell |
5,600
-533
| -9% | -$158K | 0.2% | 80 |
|
|
2016
Q3 | $1.92M | Buy |
6,133
+138
| +2% | +$40.9K | 0.24% | 62 |
|
|
2016
Q2 | $1.45M | Buy |
5,995
+1,099
| +22% | +$290K | 0.19% | 85 |
|
|
2016
Q1 | $1.27M | Buy |
4,896
+833
| +21% | +$220K | 0.16% | 103 |
|
|
2015
Q4 | $1.25M | Sell |
4,063
-211
| -5% | -$60.6K | 0.14% | 113 |
|
|
2015
Q3 | $1.25M | Sell |
4,274
-118
| -3% | -$39K | 0.17% | 101 |
|
|
2015
Q2 | $1.77M | Sell |
4,392
-108
| -2% | -$43.3K | 0.2% | 93 |
|
|
2015
Q1 | $1.9M | Sell |
4,500
-527
| -10% | -$208K | 0.21% | 91 |
|
|
2014
Q4 | $1.71M | Sell |
5,027
-67
| -1% | -$21.7K | 0.18% | 101 |
|
|
2014
Q3 | $1.69M | Buy |
5,094
+47
| +0.9% | +$15.5K | 0.19% | 99 |
|
|
2014
Q2 | $1.59M | Sell |
5,047
-36
| -0.7% | -$10.8K | 0.18% | 106 |
|
|
2014
Q1 | $1.55M | Sell |
5,083
-4,045
| -44% | -$1.28M | 0.17% | 102 |
|
|
2013
Q4 | $2.55M | Sell |
9,128
-1,159
| -11% | -$300K | 0.28% | 62 |
|
|
2013
Q3 | $2.48M | Sell |
10,287
-48
| -0.5% | -$10.7K | 0.3% | 53 |
|
|
2013
Q2 | $2.22M | Buy |
+10,335
| New | +$2.21M | 0.3% | 66 |
|
Other funds holding BIIB
Pitcairn's BIIB Position: Q4 2025 in Review
Pitcairn sold out of Biogen (BIIB) in Q4 2025, closing a stake of 10,192 shares — an estimated $1.43M sold.
Pitcairn first reported a position in BIIB in Q2 2013 and held it in 48 quarters. The position peaked at $2.55M in Q4 2013. 997 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.
- Pitcairn reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
- Pitcairn sold 10,192 Biogen shares in Q4 2025, an estimated $1.43M.
- Pitcairn first reported a position in Biogen in Q2 2013 and held it in 48 quarters.
- Pitcairn's Biogen position peaked at $2.55M in Q4 2013.
- 997 funds tracked by Wall St. Rank held Biogen as of Q4 2025.
Based on Pitcairn's 13F filing for Q4 2025.